This study evaluated the effects of haemodilution with either 6% hydroxyethyl starch (HES) 130/0.4 (Voluven®) or 0.9% normal saline (NS) on blood coagulation in vitro. Haemodilution with 6% HES 130/0.4 impaired coagulation, as indicated by the changes in thromboelastographic parameters k-time, α-angle and maximum amplitude. Light transmission aggregometry and multiple electrode aggregometry demonstrated that impaired platelet receptor function occurred only at high levels of haemodilution (40%) with both fluids, but there was no significant difference between the two fluids (P=0.05). The thromboelastographic functional fibrinogen assay showed that the fibrinogen component of clot strength was significantly impaired with haemodilution with HES 130/0.4 compared with haemodilution with NS (whole blood [14.4±4.6 mm] versus 40% HES dilution [3.7±1.9], [P=0.001]; versus 40% NS dilution [10.4±4.6], [P=0.129]). These findings suggest that there is little difference between HES or NS in relation to coagulation or platelet function during minor or moderate haemodilution, but at high levels of haemodilution with HES, fibrinogen activity is more impaired compared with NS.
Hydroxyethyl starch (HES) solutions are associated with adverse renal and coagulation effects and increased tissue deposition 1, 2 . The starch solutions decrease Factor VIII and von Willebrand factor resulting in impaired fibrinogen polymerisation and platelet dysfunction 1 . HES 130/0.4 (Voluven®, Fresenius Kabi, Hamburg, Germany), a third generation starch solution, is reported to cause less coagulation disturbance among the available starch solutions [3] [4] [5] . Systematic reviews reported that the use of HES solutions in critically ill patients was associated with increased red blood cell transfusion requirement, suggesting coagulation disturbance 6, 7 . Crystalloid solutions have no inhibitory effects on coagulation beyond that caused by haemodilution 8 .
The aims of this study were to evaluate the direct effects of 6% HES 130/0.4 on coagulation, and to determine whether these effects extend beyond that caused by haemodilution.
We compared the in vitro effects on coagulation of progressive haemodilution with HES with equivalent dilutions with 0.9% normal saline (NS) using conventional laboratory methods and thromboelastography.
Methods
Following institutional ethics committee approval (Protocol number X12-0061; HREC/12/RPAH/99) and written informed consent, 20 healthy volunteers (11 male, 9 female) aged between 18 and 65 years were recruited. Exclusion criteria included a history of liver and renal disease, bleeding disorders and the consumption of oral anticoagulants or nonsteroidal anti-inflammatory drugs within seven days of the sampling of blood.
Blood sampling
Venous blood samples were obtained from an antecubital vein with minimal stasis using a 21G needle with Vacutainer system (Becton and Dickinson, Franklin Lakes, NJ, USA) into sampling tubes containing ethylenediaminetetraacetic acid (EDTA), citrate or hirudin. To avoid the initial coagulation activation resulting from venepuncture and venous stasis, blood was first collected into the EDTA tube (for full blood count) to exclude this first 3 ml of blood from coagulation analysis (equivalent to a 'two-syringe technique').
We used the adenosine diphosphate (ADP) and adrenaline closure time measured by the Platelet Function Analyser-100® (PFA-100) (Dade-Behring, Marburg, Germany) to exclude any platelet defect 9 .
Haemodilution
The venous blood samples were diluted in fixed proportion by 1:9 (10%), 1:4 (20%) and 1:1.5 (40%) with either 0.9% NS or 6% HES 130/0.4.
Thromboelastography
Whole blood coagulation was analysed using the Thromboelastograph® (TEG) (Haemoscope Corp, Niles, IL, USA), a point-of-care test of the viscoelastic properties of whole blood 10 . The venous blood samples for thromboelastography were stabilised in citrate for 30 minutes and then re-calcified with 20 µl of calcium chloride (0.2 mol/l) after haemodilution, and then kaolin activation performed according to the manufacturer's instructions 11 .
The TEG parameters measured included the r-time (time to clot initiation), k-time (clot kinetics), α-angle (a clot acceleration measurement), and maximum amplitude (MA) (maximal clot strength measurement).
The functional fibrinogen maximal amplitude (FFMA), a measurement of maximum clot strength after the exclusion of platelet activity, was measured using the TEG functional fibrinogen assay. With the TEG functional fibrinogen assay, platelet activity is inhibited with abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) and followed by the activation of coagulation with lyophilised tissue factor [12] [13] [14] .
Platelet function studies
Light transmission aggregometry (LTA) (AggRAM analyser, Helena Laboratories, Beaumont, TX, USA) 15, 16 , and multiple electrode aggregometry (MEA) (Multiplate® Platelet Function Analyser, Dynabyte, Munich, Germany) were used to evaluate platelet function. In LTA, the increase in light transmission over time measured the responses of plateletrich plasma (PRP) to the agonists ADP and collagen. Maximal aggregation was defined as the maximum percent light transmission 17 . MEA is a semi-automated point-of-care test of platelet receptor response to specific agonists in whole blood 18, 19 . We measured MEA response to five agonists: ADP, collagen, ristocetin, arachidonic acid and thrombin receptor activating peptide (TRAP). Platelet aggregation was initiated by addition of commercially available reagents: ADPtest, adenosine diphosphate 0.2 mM; COLtest, collagen (100 μg/ ml); RISTOtest, ristocetin (0.2 mg/ml); ASPItest, arachidonic acid (15 mM), and TRAPtest, thrombin receptor activating peptide-6 (1 mM) (Dynabyte, Munich, Germany). The change in electrical impedance was measured as an area under the curve (AUC) over six minutes.
Statistical analysis
Multiple comparisons were undertaken using analysis of variance with the application of post hoc Tukey test when a significant difference was detected. The statistical analysis was performed using IBM SPPS statistics version 20.0 software (IBM, Armonk, NY, USA). Based on previously published studies 20, 21 , an estimated sample size of ten volunteers was required to provide a power of 80% at a 5% significance level to detect a 20% difference in TEG variables.
Results
The baseline haemoglobin, haematocrit, platelet count, activated partial thromboplastin time, International Normalized Ratio, fibrinogen concentration, TEG, LTA and MEA measurements were within the normal ranges. Platelet dysfunction in the volunteers was excluded by the normal MEA and LTA parameters. There was no significant difference in fibrinogen concentrations at equivalent haemodilution with HES compared with NS.
Thromboelastography
The r-time increased with progressive haemodilution with both NS and HES, but there were no significant differences in increase in r-time between NS or HES at any dilution (40% NS dilution [mean 7.9 minutes, SD±1.02] versus 40% HES dilution, [7.85±0.9 minute], P=0.9). The k-time was increasingly prolonged with progressive haemodilution with HES and this was significant at haemodilutions greater than 20% (whole-blood [mean 2.15±0. 46 The platelet response to the five agonists (ADP, collagen, ristocetin, ASPI and TRAP) measured by multiple electrode aggregometry decreased with progressive haemodilution. This was only statistically significant during 40% haemodilution with both study fluids (whole blood [80.8±21.5 AUC] versus 40% HES dilution TRAP [125.5±20.9 AUC], P=0.001, whole blood versus 40% NS dilution TRAP [92.7±18.7 AUC], P=0.001). There was no statistical difference between NS and HES dilution of whole blood when these measurements were compared with each other (40% NS dilution versus 40% HES dilution TRAP, P=0.55).
Discussion
This study showed that there was little difference in coagulation or platelet function changes during minor to moderate haemodilution with normal saline or HES. However, functional fibrinogen activity was reduced to a greater extent with HES than with NS for haemodilutions greater than 10%. For NS, the functional fibrinogen activity was significantly impaired only during haemodilution to 40% dilution. Haemodilution in excess of 40% with both diluent fluids has been reported to cause severe coagulopathy 22, 23 .
Previous studies 22, 24, 30 have reported that impaired platelet function was associated with haemodilution with the older starch solutions. However, we could not demonstrate any impaired platelet function associated with haemodilution with HES 130/0.4 using multiple electrode aggregometry with the various platelet agonists. This was confirmed by the LTA (the gold standard laboratory test) measurements.
Adequate coagulation factor levels and activity are required to produce fibrin polymers that bind activated GP IIb/IIIa platelet receptors to form a stable clot. Sossford et al showed that the activity of factor XIII (the protein which crosslinks fibrin) is adequate following 40% dilution with HES 130/0.4 31 .
Fibrinogen replacement following haemodilution can correct the hypocoagulation associated with NS or Ringer's lactate solution, but it does not correct the coagulation defect caused by HES 130/0.4 [32] [33] [34] . Fenger-Ericksen et al demonstrated that the absolute fibrinogen levels decrease in proportion to dilution regardless of the type of diluent used 35 .
As the LTA and MEA measurements in this study did not indicate any impairment of platelet receptor function associated with haemodilution with HES 130/0.4, we suggest that the reduction in clot strength (indicated by the decreased TEG MA and FFMA) may be caused by impaired fibrinogen activity. Nielsen 36 showed that when fibrinogen was added to blood haemodiluted with NS, the TEG measurements normalised and no further improvements were achieved by the addition of factor XIIIa. The same study also showed that the addition of FXIIIa and fibrinogen did not completely restore TEG measurements with HES diluted blood, confirming the findings of other studies 37, 38 .
Recent randomised controlled trials reported a higher incidence of blood product utilisation when HES 130/0.4 was used for resuscitation of patients compared with crystalloid solutions [39] [40] [41] . The International Normalized Ratio and activated partial thromboplastin time in these clinical trials did not change following HES administration, suggesting that these tests may not be useful measures of coagulation disturbance associated with haemodilution with 6% HES 130/0.4.
A major limitation of this study is the difficulty in extrapolating the in vitro changes associated with HES haemodilution demonstrated in this study to in vivo (clinical) situations. This study used tests performed under static conditions, and did not assess the influence of shear forces on the interaction of coagulation factors and the endothelium 42 . This study also did not assess the effects of the changes in electrolyte composition associated with the haemodilution.
The upper limit of haemodilution (40%) used in this study was selected because it simulated the clinical scenario when the maximal dose (30 ml/kg body weight) of HES 130/0.4 (as recommended by the Therapeutic Goods Administration of Australia) 43 is used. Significant coagulation disturbances occur as haemodilution with HES approaches the recommended maximal dose.
Conclusion
In light of increasing evidence of renal failure associated with the administration of HES 130/0.4 solutions in critically ill patients [44] [45] [46] , the use of HES 130/0.4 has declined. Our findings suggest that if HES 130/0.4 is used during major haemodilution, reduced functional fibrinogen activity may occur compared to haemodilution with NS. However, with minor to moderate haemodilution, there appears to be no significant difference between HES and NS on coagulation or platelet function. 
